Eng TR, Butler WT. Estimates of the economic burden of STDs: review of the literature with updates. The hidden epidemic: confronting sexually transmitted diseases. US: National Academies Press; 1997.
Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect cost of HIV infection in England. Clin Ther. 2000;22(11):1333–45.
Blandford JM, Gift TL. Productivity losses attributable to untreated chlamydial infection and associated pelvic inflammatory disease in reproductive-aged women. Sex Transm Dis. 2006;33(10):S117–S21.
Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, Del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43(4):451–7.
Hubben GAA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, et al. The societal burden of HIV/AIDS in northern Italy: an analysis of costs and quality of life. AIDS Care. 2008;20(4):449–55.
World Health Organization (WHO). Global health sector strategy on sexually transmitted infections 2016–2021: toward ending STIs. Geneva: World Health Organization; 2016.
Passanisi A, Leanza V, Leanza G. The impact of sexually transmitted diseases on quality of life: application of three validated measures. G Ital Ostet Ginecol. 2013;35(6):722–7.
Darroch J, Myers L, Cassell J. Sex differences in the experience of testing positive for genital chlamydia infection: a qualitative study with implications for public health and for a national screening programme. Sex Transm Infect. 2003;79(5):372–3.
Aranda-Reneo I, Rodríguez-Sánchez B, Peña-Longobardo LM, Oliva-Moreno J, López-Bastida J. Can the consideration of societal costs change the recommendation of economic evaluations in the field of rare diseases? An empirical analysis Value Health. 2020;24(3):431–42.
Remme M, Martinez-Alvarez M, Vassall A. Cost-effectiveness thresholds in global health: taking a multisectoral perspective. Value Health. 2017;20(4):699–704.
Drost R, Paulus A, Ruwaard D, Evers S. Inter-sectoral costs and benefits of mental health prevention: towards a new classification scheme. J Ment Health Policy Econ. 2013;16(4):179–86.
Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. BMC Public Health. 2013;13(1):1001.
Drummond M, Weatherly H, Claxton K, Cookson R, Ferguson B, Godfrey C, et al. Assessing the challenges of applying standard methods of economic evaluation to public health interventions. York: Public Health Research Consortium; 2007.
Weinstein MC, Russell LB, Gold MR, Siegel JE. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
Drost RM, Paulus AT, Evers SM. Five pillars for societal perspective. Int J Technol Assess Health Care. 2020;36(2):72–4.
Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974–2018. Pharmacoeconomics. 2020;38(10):1135–45.
Krol M, Papenburg J, Tan SS, Brouwer W, Hakkaart L. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. Eur J Health Econ. 2016;17(4):391–402.
Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Med Care. 2009;47(7):28–32.
Trapero-Bertran M, Oliva-Moreno J. Economic impact of HIV/AIDS: a systematic review in five European countries. Heal Econ Rev. 2014;4(1):1–16.
Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, et al. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy. 2009;93(2–3):85–92.
Chesson HW. Cost effectiveness of one to one STI prevention interventions. Med Soc Study Vener Dis. 2007;83(6):423–4.
Centre for Reviews and Dissemination UoY. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination, University of York; 2009.
van Mastrigt GA, Hiligsmann M, Arts JJ, Broos PH, Kleijnen J, Evers SM, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704.
Thielen F, Van Mastrigt G, Burgers L, Bramer W, Majoie H, Evers S, et al. How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):705–21.
Wijnen B, Van Mastrigt G, Redekop W, Majoie H, De Kinderen R, Evers S. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):723–32.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
World Health Organization. Adolescent health. Available from: https://www.who.int/health-topics/adolescent-health#tab=tab_1.
Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240.
Roberts T, Henderson J, Mugford M, Bricker L, Neilson J, Garcia J. Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness. BJOG. 2002;109(1):44–56.
Inflation Tool [Available from: https://www.inflationtool.com/.
Currency Converter [Available from: https://www.xe.com/.
National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. United Kingdom: National Institute for Health and Care Excellence; 2013.
Ginsberg G, Chemtob D. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. BMC Public Health. 2020;20(1):1–14.
van Luenen S, Kraaij V, Garnefski N, Spinhoven P, van den Akker–van ME. Cost-utility of a guided internet-based intervention in comparison with attention only for people with HIV and depressive symptoms: a randomized controlled trial. J Psychosom Res. 2019;118:34–40.
Zulliger R, Maulsby C, Solomon L, Baytop C, Orr A, Nasrullah M, et al. Cost-utility of HIV testing programs among men who have sex with men in the United States. AIDS Behav. 2017;21(3):619–25.
Wijnen BF, Oberjé EJ, Evers SM, Prins JM, Nobel H-E, van Nieuwkoop C, et al. Cost-effectiveness and cost-utility of the adherence improving self-management strategy in human immunodeficiency virus care: a trial-based economic evaluation. Clin Infect Dis. 2019;68(4):658–67.
Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, et al. The cost-effectiveness of financial incentives for viral suppression: HPTN 065 study. Value Health. 2019;22(2):194–202.
Damm O, Horn J, Mikolajczyk RT, Kretzschmar ME, Kaufmann AM, Deleré Y, et al. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Eff Resour Allocation. 2017;15(1):1–19.
de Wit GA, Over EA, Schmid BV, van Bergen JE, van den Broek IV, van der Sande MA, et al. Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands. Sex Transm Infect. 2015;91(6):423–9.
Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. A cost-effectiveness analysis of preexposure prophylaxis for the prevention of HIV among Los Angeles County men who have sex with men. Clin Infect Dis. 2016;63(11):1495–504.
Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884
Nosyk B, Min J, Lima V, Hogg R, Montaner J. Modelling the cost-effectiveness of population-level HAART expansion in British Columbia. Lancet HIV. 2015;2(9):e393.
Owusu-Edusei K Jr, Chesson HW, Gift TL, Brunham RC, Bolan G. Cost-effectiveness of Chlamydia vaccination programs for young women. Emerg Infect Dis. 2015;21(6):960.
Owusu-Edusei K Jr, Hoover KW, Gift TL. Cost-effectiveness of opt-out Chlamydia testing for high-risk young women in the US. Am J Prev Med. 2016;51(2):216–24.
Zechmeister I, de Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133–41.
Gift TL, Kissinger P, Mohammed H, Leichliter JS, Hogben M, Golden MR. The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea. Sex Transm Dis. 2011;38(11):1067–73.
Wolff E, Elfström KM, Cange HH, Larsson S, Englund H, Sparén P, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine. 2018;36(34):5160–5.
Campos NG, Scarinci IC, Tucker L, Peral S, Li Y, Regan MC, et al. Cost-effectiveness of offering cervical cancer screening with HPV self-sampling among African-American women in the Mississippi Delta. Cancer Epidemiol Prev Biomark. 2021;30(6):1114–21.
Régnier SA, Huels J. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Hum Vaccin Immunother. 2014;10(12):3737–45.
Mahumud RA, Alam K, Dunn J, Gow J. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia. PLoS One. 2019;14(10):e0223658.
de Kok IM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101(15):1083–92.
Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151(8):538–45.
Rogoza R, Westra T, Ferko N, Tamminga J, Drummond M, Daemen T, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine. 2009;27(35):4776–83.
Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One. 2013;8(10):e78548.
Rours G, Smith-Norowitz TA, Ditkowsky J, Hammerschlag MR, Verkooyen R, de Groot R, et al. Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women. Pathog Glob Health. 2016;110(7–8):292–302.
Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, et al. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis. 2019;19(1):1–13.
van Wifferen F, Hoornenborg E, van der Loeff MFS, Heijne J, van Hoek AJ. Cost-effectiveness of two screening strategies for Chlamydia trachomatis and Neisseria gonorrhoeae as part of the PrEP programme in the Netherlands: a modelling study. Sex Transm Infect. 2021;97(8):607–12.
Fogelberg S, Clements MS, Pedersen K, Sy S, Sparén P, Kim JJ, et al. Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden. PLoS One. 2020;15(9):e0239611.
Coupé VM, de Melker H, Snijders PJ, Meijer CJ, Berkhof J. How to screen for cervical cancer after HPV16/18 vaccination in the Netherlands. Vaccine. 2009;27(37):5111–9.
Deogan CL, Hansson Bocangel MK, Wamala SP, Månsdotter AM. A cost-effectiveness analysis of the Chlamydia Monday-a community-based intervention to decrease the prevalence of chlamydia in Sweden. Scand J Public Health. 2010;38(2):141–50.
Ouellet E, Durand M, Guertin JR, LeLorier J, Tremblay CL. Cost effectiveness of ‘on demand’HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol. 2015;26(1):23–9.
Owusu-Edusei K, Roby TM, Chesson HW, Gift TL. Productivity costs of nonviral sexually transmissible infections among patients who miss work to seek medical care: evidence from claims data. Sex Health. 2013;10(5):434–7.
Weatherly H. Assessing the challenges of applying standard methods of economic evaluation to public health interventions. 2009. Available at SSRN 991835.
Drummond M, Weatherly H, Ferguson B. Economic evaluation of health interventions. BMJ. 2008;337.
de Vries LM, van Baal PH, Brouwer WB. Future costs in cost-effectiveness analyses: past, present, future. Pharmacoeconomics. 2019;37(2):119–30.
Vlassoff M, Singh S, Darroch JE, Carbone E, Bernstein S. Assessing costs and benefits of sexual and reproductive health interventions; 2004.
Newton D, Bayly C, Fairley C, Chen M, Williams H, Keogh L, et al. The impact of pelvic inflammatory disease on sexual, reproductive and psychological health. BMJ Publishing Group Limited. 2011;8:233.
Bloch SC, Jackson LJ, Frew E, Ross JD. Assessing the costs and outcomes of control programmes for sexually transmitted infections: a systematic review of economic evaluations. Sex Transm Infect. 2021;97(5):334–44.
Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31(7):537–49.
Shepherd J, Kavanagh J, Picot J, Cooper K, Harden A, Barnett-Page E, et al. The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluation. Health Technol Assess. 2010;14(7):1–206 iii-iv.
Chong A, Gonzalez-Navarro M, Karlan D, Valdivia M. Effectiveness and spillovers of online sex education: evidence from a randomized evaluation in Colombian public schools. NBER Working Pap Ser. 2013:18776.
Schnitzler L, Janssen LM, Evers SM, Jackson LJ, Paulus AT, Roberts TE, et al. The broader societal impacts of COVID-19 and the growing importance of capturing these in health economic analyses. Int J Technol Assess Health Care. 2021;37(1):E43.
Bonanni P, Picazo JJ, Rémy V. The intangible benefits of vaccination–what is the true economic value of vaccination? J Market Access Health Policy. 2015;3(1):26964.